Jounce Therapeutics Stock Forecast, Price & News

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, JNCE shares have increased by 69.9% and is now trading at $7.27.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Jounce Therapeutics.

Wall Street analysts have given Jounce Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jounce Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Jounce Therapeutics.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its quarterly earnings data on Friday, November, 6th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.36.
View Jounce Therapeutics' earnings history.

5 equities research analysts have issued twelve-month target prices for Jounce Therapeutics' shares. Their forecasts range from $9.00 to $15.00. On average, they anticipate Jounce Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 65.1% from the stock's current price.
View analysts' price targets for Jounce Therapeutics.

Jounce Therapeutics saw a decline in short interest in the month of October. As of October 15th, there was short interest totaling 954,200 shares, a decline of 40.0% from the September 30th total of 1,590,000 shares. Based on an average daily volume of 1,210,000 shares, the days-to-cover ratio is presently 0.8 days. Approximately 5.8% of the shares of the company are short sold.
View Jounce Therapeutics' Short Interest.

Some companies that are related to Jounce Therapeutics include Vericel (VCEL), Inhibrx (INBX), Alector (ALEC), NantKwest (NK), Cellectis (CLLS), Krystal Biotech (KRYS), TCR2 Therapeutics (TCRR), BioCryst Pharmaceuticals (BCRX), Passage Bio (PASG), Compugen (CGEN), Taysha Gene Therapies (TSHA), Cardiff Oncology (CRDF), Vaxart (VXRT), Poseida Therapeutics (PSTX) and Agenus (AGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.55%), Acadian Asset Management LLC (2.51%), Candriam Luxembourg S.C.A. (1.04%), State Street Corp (0.98%), Charles Schwab Investment Management Inc. (0.78%) and AQR Capital Management LLC (0.51%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray and Rock Ventures Ii LP Third.
View institutional ownership trends for Jounce Therapeutics.

JNCE stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., BlackRock Inc., AXA S.A., State Street Corp, JPMorgan Chase & Co., and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, and Rock Ventures Ii LP Third.
View insider buying and selling activity for Jounce Therapeutics.

JNCE stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Hussman Strategic Advisors Inc., Ziegler Capital Management LLC, Cubist Systematic Strategies LLC, First Trust Advisors LP, Arrowstreet Capital Limited Partnership, Dupont Capital Management Corp, and Raymond James & Associates.
View insider buying and selling activity for Jounce Therapeutics.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of JNCE stock can currently be purchased for approximately $7.27.

Jounce Therapeutics has a market capitalization of $289.72 million and generates $147.87 million in revenue each year. The company earns $56.82 million in net income (profit) each year or $1.66 on an earnings per share basis. Jounce Therapeutics employs 130 workers across the globe.

The official website for Jounce Therapeutics is www.jouncetx.com.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.